Human Umbilical Cord Blood for Transplantation Therapy in Myocardial InfarctionSandra A Acosta1#, Nick Franzese1#, Meaghan Staples1#, Nathan L Weinbren1#, Monica Babilonia1, Jason Patel1, Neil Merchant1, Alejandra JacotteSimancas1, Adam Slakter1, Mathew Caputo1, Milan Patel1, Giorgio Franyuti1, Max H Franzblau1, Lyanne Suarez1, Chiara Gonzales- Portillo1, Theo Diamandis1, Kazutaka Shinozuka1, Naoki Tajiri1, Paul R. Sanberg1, Yuji Kaneko1, Leslie W Miller2 and Cesar V Borlongan1*
- *Corresponding Author:
- Cesar V. Borlongan PhD
Professor and Vice-Chairman for Research
Department of Neurosurgery and Brain Repair
University of South Florida
12901 Bruce B. Downs Blvd., Tampa 33612, FL , USA
Tel: +1 813 974 3154
Fax: +1 813 974 3078
E-mail: [email protected]
Received date: June 04, 2013; Accepted date: June 28, 2013; Published date: July 01, 2013
Citation: Acosta SA, Franzese N, Staples M, Weinbren NL, Babilonia M, et al. (2013) Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction. J Stem Cell Res Ther S4:005. doi:10.4172/2157-7633.S4-005
Copyright: © 2013 Acosta SA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cell-based therapy is a promising therapy for myocardial infarction. Endogenous repair of the heart muscle after myocardial infarction is a challenge because adult cardiomyocytes have a limited capacity to proliferate and replace damaged cells. Pre-clinical and clinical evidence has shown that cell based therapy may promote revascularization and replacement of damaged myocytes after myocardial infarction. Adult stem cells can be harvested from different sources including bone marrow, skeletal myoblast, and human umbilical cord blood cells. The use of these cells for the repair of myocardial infarction presents various advantages over other sources of stem cells. Among these are easy harvesting, unlimited differentiation capability, and robust angiogenic potential. In this review, we discuss the milestone findings and the most recent evidence demonstrating the therapeutic efficacy and safety of the transplantation of human umbilical cord blood cells as a stand-alone therapy or in combination with gene therapy, highlighting the importance of optimizing the timing, dose and delivery methods, and a better understanding of the mechanisms of action that will guide the clinical entry of this innovative treatment for ischemic disorders, specifically myocardial infarction.